Hearing loss: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• GLP-1 0
• PD-1 0
• SGLT2 0
• ABL1 0
• AMPK 0
• CGRP 0
• ERK 0
• JAK 0
• mTOR 0
• NLRP3 0
• SHP2 0
• STAT3 0
• STING 0
• VEGF 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  REstoring VIsion via native-Code-Aligned Neurostimulation (REVICAN)

  Univerzita Karlova· Praha 1, Csehország· EU contribution 731 460 EUR· until 2030. szept.· 9 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Visual Hearing for Context-Aware Cognitive Audio Technology (WeHear)

  Danmarks Tekniske Universitet· Kongens Lyngby, Dánia· EU contribution 5 411 208 EUR· until 2029. aug.· 5 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Unlocking bio-inspired machine hearing and accelerating personalized hearing technologies (InSilicoEars)

  Universiteit Gent· Gent, Belgium· EU contribution 1 999 712 EUR· until 2031. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Watts in my ear? Unravelling the power source of mammalian hearing. (ActivEAR)

  Universidad Autonoma de Madrid· Madrid, Spanyolország· EU contribution 1 923 556 EUR· until 2031. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Advancing a scalable and multifactorial exosome therapy to address the unmet needs of drug-induced hearing loss (EXO-OTOProtect)

  Exogenus Therapeutics Sa· Cantanhede, Portugália· EU contribution 500 000 EUR· until 2028. febr.

5 of 21 running projects, newest first. Listed amounts together: 41,9 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 4
• Organoids 12
• Mendelian Randomization Analysis 16
• CRISPR-Cas Systems 6
• Gene Expression Profiling 18
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 6
• Exome Sequencing 75
• Proteomics 10
• Metabolomics 9
• Mass Spectrometry 1
• Immunohistochemistry 12
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 4
• Magnetic Resonance Imaging 162
• Machine Learning 37
• Deep Learning 20
• Cohort Studies 95
• Genome-Wide Association Study 23

• Echoes of Renewal: Rebuilding the Mammalian Inner Ear.

  Ear Hear, 2026. okt.

• Advances in Stem Cell Therapy for Hearing Loss.

  Ear Hear, 2026. okt.

• Inner Ear Organoids: Recent Progress and Challenges.

  Stem Cell Rev Rep, 2026. aug.

• Engineering Pluripotent Stem Cells-Derived Inner Ear Organoids With Enhanced Maturation and Reproducibility by Micro-Topographical Cues.

  Adv Mater, 2026. aug.

• CLRN1 Variants in Müller Cells Cause Mitochondrial Dysfunction in USH3A Retinal Organoids.

  CNS Neurosci Ther, 2026. aug.

• Single-cell analysis reveals impaired Müller glia-mediated intercellular communication and photoreceptor pathology in USH1C retinal organoids.

  Cell Mol Life Sci, 2026. júl.

• Dopamine-modified Ti3C2Tx MXene promotes supporting cell pluripotency and hair cell regeneration in cochlear organoid culture.

  Biomaterials, 2026. máj.

• Human induced pluripotent stem cell-derived inner ear organoids reveal hair cell damage and plasticity after cisplatin and gentamicin exposure.

  Dis Model Mech, 2026. márc.

• Thyroid hormone augmentation accelerates hair cell maturation in human cochlear organoids.

  Cell Rep, 2026. jan.

• Engineering vascularized inner ear organoids: Challenges and advances in recapitulating the cochlear microenvironment.

  Biomaterials, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.